Cephalosporin derviatives

US5620969A · kind A · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Joanne J. Bronson · Madison, US
• Stanley D'Andrea · Middletown, US
• Shelley E. Hoeft · Middletown, US
• John D. Matiskella · Wallingford, US
• Peter F. Misco · Syracuse, US
• Bing Yu Luh · Killingworth, US
• Dane M. Springer · Yardley, US
• Yasutsugu Ueda · Clinton, US
• John A. Wichtowski · Saint Albans, US

Key dates

• Filing date: Apr 25, 1995
• Grant date: Apr 15, 1997
• Expiry date: Apr 25, 2015

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D501/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Novel cephem derivatives represented by the general formula ##STR1## in which the Acyl substituent is a group of the formula ##STR2## wherein Ar is a lipophilic optionally substituted phenyl, naphthyl or pyridyl group; R.sup.1 represents either the residue of a heterocyclic amino acid or a C.sub.2 -C.sub.10 alkyl group substituted by both a carboxyl group and a group of the formula --NR.sup.9 R.sup.10 or ##STR3## in which R.sup.9 and R.sup.10 are each independently hydrogen or C.sub.1 -C.sub.6 alkyl, said C.sub.2 -C.sub.10 alkyl group being optionally interrupted by one or more nitrogen atoms or carbonyl groups, and R.sup.2 and R.sup.3 are each independently hydrogen, alkyl or aminoalkyl are gram-positive antibacterial agents, especially useful in the treatment of diseases caused by methicillin-resistant Staphylococcus aureus (also referred to below as MRSA or methicillin-resistant S. aureus).